Literature DB >> 15274900

[Consumption of antibiotics and their possible relationship with bacterial resistance in the "Costa de Ponent" health region: analysis of evolution through the initial and end periods of the last decade].

J Solé López1, G Rodríguez Palomar, V Grahit Vidosa, E Juncadella García.   

Abstract

OBJECTIVE: To analyse antibiotic consumption (ABC) and its trend in primary care in an area with a high rate of bacterial resistance during the periods 1993-96 and 2000-02.
DESIGN: Comparative, retrospective analysis.
SETTING: Costa de Ponent Health Region. Population in 1993-96 period was 1,158,098 inhabitants; in 2000-02 period, 1,188,007 inhabitants. PARTICIPANTS: Those patients in the Area who took AB during the periods under study. MEASUREMENTS: Data obtained from the appropriate records of the Catalan Health Service. Measurement of ABC was the Defined Daily Dose (DDD)/1000 inhabitants/day (DID) [criteria of the WHO Collaborating Centre for Drugs Statistics Methodology]. Trends were quantified as percentage increase or drop, comparing the 1993-96 and 2000-02 periods. The U Mann-Whitney test was used.
RESULTS: Overall consumption was high, with a light fall from 17.049 DID during the first period to 15.826 DID in the second (-7.1%). Amoxycillin increased from 4.878 DID (57.6%) to 6.19 DID (67.6%) (+26.8%), but amoxycillin-clavulanic did not rise. The percentages of macrolides, quinolones, cephalosporins, sulphonamides, and tetracyclines were higher in the first period. The variations in the consumption of clarithromycin, azithromycin, cefuroxime, cefixime, and ciprofloxacin between the two periods was the most notable point.
CONCLUSIONS: Although overall ABC was high and in accord with the high rate of bacterial resistance in our area, a satisfactory evolutionary trend was found. The fall in consumption in the second period was not significant, but an appropriate modification in its profile was noted: domination of aminopenicillins and drop in macrolides, cephalosporins and fluorquinolones.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15274900      PMCID: PMC7668728          DOI: 10.1016/s0212-6567(04)79482-2

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  8 in total

1.  Non-hospital consumption of antibiotics in Spain: 1987-1997.

Authors:  A R Bremón; M Ruiz-Tovar; B P Gorricho; P D de Torres; R L Rodríguez
Journal:  J Antimicrob Chemother       Date:  2000-03       Impact factor: 5.790

2.  [Antibiotic consumption (1993-1996) in primary care in a health area with a high rate of bacterial resistance].

Authors:  F J Millet Medina; S Gracia Aguirre; R Madridejos Mora; J Solé López
Journal:  Aten Primaria       Date:  1998-04-30       Impact factor: 1.137

3.  Antibiotic resistance worldwide--a Spanish task force responds.

Authors:  S B Levy
Journal:  Clin Infect Dis       Date:  1996-10       Impact factor: 9.079

4.  Antibiotic resistance in Spain: what can be done? Task Force of the General Direction for Health Planning of the Spanish Ministry of Health.

Authors:  F Baquero
Journal:  Clin Infect Dis       Date:  1996-10       Impact factor: 9.079

5.  [Changes in the use of antibacterial agents in Catalonia, Impact of new marketed drugs].

Authors:  J C Llop
Journal:  Aten Primaria       Date:  1997-03-31       Impact factor: 1.137

6.  Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997).

Authors:  J J Granizo; L Aguilar; J Casal; C García-Rey; R Dal-Ré; F Baquero
Journal:  J Antimicrob Chemother       Date:  2000-11       Impact factor: 5.790

7.  A European study on the relationship between antimicrobial use and antimicrobial resistance.

Authors:  Stef L A M Bronzwaer; Otto Cars; Udo Buchholz; Sigvard Mölstad; Wim Goettsch; Irene K Veldhuijzen; Jacob L Kool; Marc J W Sprenger; John E Degener
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

8.  Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.

Authors:  C Peña; J M Albareda; R Pallares; M Pujol; F Tubau; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.